Stock Movers

On this episode of Stock Movers, we look at some of the week's biggest gainers and decliners:
- Amazon (AMZN) shares surged after the company reported cloud-computing revenue accelerated for a fifth straight quarter, easing investors’ concerns that it won’t produce a return on huge expenditures to meet the booming demand for artificial intelligence.
- Roblox (RBLX) shares tumbled by as much as 26% as trading got underway in New York, the largest intraday decline in roughly four-and-a-half years, after the gaming company reported second-quarter daily active users that missed analysts’ expectations, reflecting the ongoing impact of new child-safety measures.
- Chipotle (CMG) raised its annual guidance after bringing back its popular honey chicken and overhauling its rewards program. The chain now expects sales from locations open at least 13 months to rise in the low single-digit range this year, Chipotle said Wednesday. An earlier forecast called for the metric, known as comparable sales, to be about flat.
See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Katie Greifeld, Carol Massar and Tim Stenovec.
- Amazon (AMZN) shares surged the most since 2012 after the company reported accelerating cloud-computing revenue, easing investors’ concerns that it won’t produce a return on huge expenditures to meet the booming demand for artificial intelligence.
- Apple (AAPL) tumbled by the most in 16 months after component shortages weighed on the company’s sales forecast, signaling that industrywide supply constraints are taking a bigger toll than anticipated. The disappointing forecast sent Apple shares down as much as 9.5% to $301.83 at the market open on Friday, their biggest intraday drop since April 3, 2025.
- Roblox (RBLX) shares tumbled by as much as 26% as trading got underway in New York, the largest intraday decline in roughly four-and-a-half years, after the gaming company reported second-quarter daily active users that missed analysts’ expectations, reflecting the ongoing impact of new child-safety measures.
See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Apple (AAPL) shares tumbled by the most in 16 months after component shortages weighed on the company’s sales forecast, signaling that industrywide supply constraints are taking a bigger toll than anticipated.
- Amazon (AMZN) shares surged after the company reported cloud-computing revenue accelerated for a fifth straight quarter, easing investors’ concerns that it won’t produce a return on huge expenditures to meet the booming demand for artificial intelligence.
- Novo Nordisk (NVO)'s experimental drug failed to reduce the risk of heart attacks and strokes in a large study, a blow to the drugmaker’s growth prospects beyond obesity and diabetes. The shot called ziltivekimab reduced the protein it was targeting in the body, but that didn’t translate into an impact on the risk of severe cardiovascular problems in the late-stage clinical trial, the Danish drugmaker said Friday. Analysts had widely expected at least some benefit, though there had been debate over how large it would be. Novo shares fell as much as 10.5%, the most since February.
See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Apple (AAPL) tumbled after component shortages weighed on the company’s sales forecast, signaling that industrywide supply constraints are taking a bigger toll than anticipated. Revenue will rise 9% to 11% in the fiscal fourth quarter, which is lower than analysts' estimates of more than 12% growth, due to constraints and currency fluctuations.
- Amazon (AMZN) shares surged after the company reported cloud-computing revenue accelerated for a fifth straight quarter, easing investors’ concerns that it won’t produce a return on huge expenditures to meet the booming demand for artificial intelligence. Revenue jumped 37% to $42.2 billion at Amazon Web Services, which generates about a fifth of the company’s revenue and most of its operating profit.
- Novo Nordisk (NVO) shares fall. A Novo Nordisk A/S experimental drug failed to reduce the risk of heart attacks and strokes in a large study, a blow to the drugmaker’s growth prospects beyond obesity and diabetes. The shot called ziltivekimab reduced the protein it was targeting in the body, but that didn’t translate into an impact on the risk of severe cardiovascular problems in the late-stage clinical trial, the Danish drugmaker said Friday.
See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Apple (AAPL) tumbled after component shortages weighed on the company’s sales forecast, signaling that industrywide supply constraints are taking a bigger toll than anticipated. Revenue will rise 9% to 11% in the fiscal fourth quarter, which is lower than analysts' estimates of more than 12% growth, due to constraints and currency fluctuations.
- Amazon (AMZN) shares surged after the company reported cloud-computing revenue accelerated for a fifth straight quarter, easing investors’ concerns that it won’t produce a return on huge expenditures to meet the booming demand for artificial intelligence. Revenue jumped 37% to $42.2 billion at Amazon Web Services, which generates about a fifth of the company’s revenue and most of its operating profit.
- Replimune (REPL) shares jumped 133% in premarket trading after the drug developer said its experimental therapy won support from an FDA advisory panel for the treatment of advanced melanoma. The outcome spurred an upgrade at Cantor. Replimune said the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 10 to 3 that the efficacy results from the firm’s IGNYTE trial are clinically meaningful.
See omnystudio.com/listener for privacy information.